PAR1产品信息
英文名称：Protease-activated receptor-1
中文名称：蛋白酶活化受体1
靶点别称：PAR1
物种：Human
属性：Protein
标记：Unconjugated/GFP Fusion
表达区间及表达系统（Source）
Human PAR1 Full Length Protein-VLP (PA1-H52P6) is expressed from human 293 cells (HEK293). It contains AA Ser 42 - Thr 425 (Accession # P25116-1).
Predicted N-terminus: Asp
蛋白结构（Molecular Characterization）
The protein has a calculated MW of 91.2 kDa | 56.1 kDa.
Virus-like particles(VLPs) are formed by self-assembly of envelop/capsid proteins from viruses. Membrane Proteins can be constituted in-situ with VLPs produced from HEK293 cell cultures. These VLPs concentrate conformationally intact membrane proteins directly on the cell surface and produce soluble, high-concentration proteins perfect for immunization and antibody screening.
The VLPs provide the display of properly folded membrane proteins in their native cellular membrane in a compact size of 100~300 nm diameter (similar to the size of most viruses) making it optimal targets for dendritic cells in vivo and surface attachment for phage display.
内毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
制剂（Formulation）
The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).
Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
运输（Shipping）
This product is supplied and shipped with dry ice, please inquire the shipping cost.
存储（Storage）
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
The product MUST be stored at -70°C or lower upon receipt;
-70°C for 12 months under sterile conditions.
背景（Background）
凝血因子II受体是一种参与调节血栓形成反应的7跨膜受体。蛋白酶切割导致受体激活。F2R是G蛋白偶联受体家族成员。选择性剪接导致多种转录变体。
关键字： PAR1;PAR1蛋白;PAR1蛋白酶;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group（股票代码：301080）是成立于2010年的跨国生物科技公司，是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球，横跨亚洲、北美洲、欧洲，在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家，与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。